BiotechTube

Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Intra-abdominal Infections

Conditions

Complicated Intra-abdominal Infections

Trial Timeline

Mar 20, 2019 → Oct 14, 2020

NCT ID
NCT03830333

About Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo

Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo is a phase 3 stage product being developed by Merck for Complicated Intra-abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03830333. Target conditions include Complicated Intra-abdominal Infections.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03830333Phase 3Completed

Competing Products

20 competing products in Complicated Intra-abdominal Infections

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
33
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
77
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
52
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85
CXA-201 and metronidazole + MeropenemMerckPhase 3
77
CXA-101 + CeftazidimeMerckPhase 2
52
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
52
Imipenem+Cilastatin/RelebactamMerckPhase 3
77
Daptomycin + VancomycinMerckApproved
85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
52
CXA-201 + LevofloxacinMerckPhase 3
77
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
77
KLU156 + CoartemNovartisPhase 3
77
LYS228 + Standard of care therapyNovartisPhase 2
52
Artemether-lumefantrine (COA566)NovartisPhase 2/3
65
INE963NovartisPhase 2
52
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
52
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85